CoChat
Cited by 181

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study

Open access
Sanchez, Alejandro, Furberg, Helena, Kuo, Fengshen, Vuong, Lynda, Ged, Yasser, Patil, Sujata, Ostrovnaya, Irina, Petruzella, Stacey, Reising, Albert, Patel, Parul, Mano, Roy, Coleman, Jonathan, Russo, Paul, Liu, Catherine H, Dannenberg, Andrew J, Chan, Timothy A, Motzer, Robert, Voss, Martin H, Hakimi, A Ari · 2020 · The Lancet Oncology

Abstract

Summary Background Obesity is associated with an increased risk of developing clear cell renal cell carcinoma (ccRCC) but, paradoxically, with improved oncologic outcomes. As the biologic mechanisms underlying this association are poorly understood, our study aimed to identify transcriptomic differences in primary tumor or peritumoral adipose tissue between obese and normal weight patients. Methods After confirming the inverse association between body mass index (BMI ≥ 30 vs < 30 kg/m2) and mortality in three independent clinical cohorts including 453 metastatic ccRCC patients treated with first-line VEGF-directed therapy from the Phase III COMPARZ clinical trial, 152 predominately early stage ccRCC patients from the Cancer Genome Atlas (TCGA), and a Memorial Sloan Kettering (MSK) observational cohort of 203 metastatic ccRCC patients treated with targeted immunotherapy using the Kaplan–Meier method and analyzed by log-rank test, we evaluated and validated primary tumor transcriptomic differences. We also compared gene expression differences in peritumoral adipose tissue from a prospectively collected cohort of patients with non-metastatic ccRCC. Wilcoxon rank-sum test was used to analyze significant differences in gene expression between groups and false discovery correction was performed using the Benjamini-Hochberg procedure. Findings A lower mortality rate was observed in obese patients versus normal weight patients in the in the locally advanced The Cancer Genome Atlas cohort (median OS not-reached (NR), 95%CI 53.45-NR vs 25.30 mos, 95%CI 14.18–39.47, respectively; adjusted-Hazard Ratio (aHR) 0·41, 95%CI 0·22–0·75), and COMPARZ trial cohort of metastatic ccRCC treated with tyrosine kinase inhibitors (median OS 35.65, 95%CI 27.66-NR vs 19.06, 95%CI 15.31–27.80, respectively; aHR 0·68, 95%CI 0·48–0·96). In a cohort of metastatic ccRCC patients treated with immunotherapy, the inverse association with OS was no longer significant after adjustment for International Metastatic Database Consortium risk score (median OS 49.87, 95%CI 31.77-NR vs. 15.61, 95%CI 11.71–30.20, respectively; aHR 0·72, 95%CI 0·40–1·30). Tumors of obese patients were characterized by increased angiogenesis expression (false discovery rate-adjusted p-value=0·01) but showed no significant differences in immune cell programs. We found increased peritumoral adipose tissue inflammation (p<0.05) in obese versus normal weight patients. Interpretation Tumor microenvironmental differences in both the tumor and peritumoral adipose tissue by BMI may contribute to the apparent survival advantage experienced by obese ccRCC patients. The complex interplay between the ccRCC tumor and peritumoral adipose tissue microenvironment may have clinical relevance and warrants further investigation. Funding Ruth L. Kirschstein Research Service Award, ACSO YIA, Ludwig Center MSK, Weiss Family Kidney Research Fund, Novartis, The Sidney Kimmel Center for Prostate and Urologic Cancers and the NIH/NCI to MSKCC through the Cancer Center Support Grant.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(19)30797-1

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 181

Metadata

Authors
Sanchez, A., Furberg, H., Kuo, F., Vuong, L., Ged, Y., Patil, S., Ostrovnaya, I., Petruzella, S., Reising, A., Patel, P., Mano, R., Coleman, J., Russo, P., Liu, C. H., Dannenberg, A. J., Chan, T. A., Motzer, R., Voss, M. H., & Hakimi, A. A.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-02
Volume
21
Issue
2
Pages
283-293
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2994822278
Cited by
181
References
16
FWCI
15.65
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(19)30797-1
The paper
Sanchez, A., Furberg, H., Kuo, F., Vuong, L., Ged, Y., Patil, S., Ostrovnaya, I., Petruzella, S., Reising, A., Patel, P., Mano, R., Coleman, J., Russo, P., Liu, C. H., Dannenberg, A. J., Chan, T. A., Motzer, R., Voss, M. H., & Hakimi, A. A. (2020). Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(19)30797-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.